Peritoneal GATA6+ macrophage drives hepatic immunopathogenesis and maintains the Treg cell niche in the liver

Hao Chang1, Yangyue Ni1, Chunxiang Shen1

  • 1State Key Laboratory of Reproductive Medicine, Department of Pathogen Biology and Immunology, Jiangsu Province Key Laboratory of Modern Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu, China.

Immunology
|June 11, 2022
PubMed

Insights

Peritoneal macrophages, specifically GATA6+ cells, drive liver disease by recruiting regulatory T cells (Tregs). Inhibiting monocyte chemoattractant proteins (MCPs) reduces this recruitment and liver pathology.

Area of Science:

  • Immunology
  • Hepatology
  • Cell Biology

Background:

  • The origin of macrophages in liver disease is unclear.
  • Understanding macrophage sources is crucial for treating hepatic immunopathology.

Purpose of the Study:

  • To investigate the role of peritoneal macrophages in liver disease development.
  • To elucidate the functional mechanism of peritoneal macrophages in hepatic immunopathology.

Main Methods:

  • Used mouse models of Schistosoma japonicum infection and carbon tetrachloride-induced liver injury.
  • Administered clodronate liposomes to deplete peritoneal macrophages and performed adoptive transfer.
  • Utilized bindarit to inhibit monocyte chemoattractant protein (MCP) synthesis.

Main Results:

  • Identified the peritoneal cavity as a key source of hepatic macrophages during liver injury.
  • Demonstrated that GATA6+ peritoneal macrophages accumulate in injured livers and contribute to pathology.
  • Showed that depleting peritoneal macrophages attenuates liver injury, while transfer exacerbates it.
  • Found that MCPs recruit GATA6+ macrophages, and their inhibition reduces liver pathology.
  • Established that peritoneal macrophages promote liver immunopathology via regulatory T cell (Treg) accumulation.

Conclusions:

  • GATA6+ peritoneal macrophages are critical drivers of hepatic immunopathology.
  • Peritoneal macrophages promote liver inflammation and disease progression by increasing Treg accumulation.
  • Targeting peritoneal macrophages or MCPs may offer therapeutic strategies for liver disease.